Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | PRKCA | P17252 | 2/20 | 0.47 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | F9 | P00740 | 1/20 | 0.43 |
| ▸ | F10 | P00742 | 1/20 | 0.43 |
| ▸ | PLAU | P00749 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27446892 | 0.87 | CYP1A2 (0.56) | CYP1A2CYP2D6PKMSMN1; SMN2NPSR1 | |
| SCHEMBL24574540 | 0.84 | CYP1A2 (0.76) | CYP1A2CYP2D6PKMSMN1; SMN2NPSR1 | |
| SCHEMBL8099464 | 0.84 | SMN1; SMN2 (0.51) | CYP1A2CYP2D6PKMSMN1; SMN2NPSR1 | |
| SCHEMBL8099913 | 0.84 | SMN1; SMN2 (0.51) | CYP1A2CYP2D6PKMSMN1; SMN2NPSR1 | |
| SCHEMBL742603 | 0.81 | CYP1A2 (0.56) | CYP1A2CYP2D6PKMSMN1; SMN2NPSR1 | |
| SCHEMBL8103307 | 0.81 | CYP1A2 (0.56) | CYP1A2CYP2D6PKMSMN1; SMN2NPSR1 | |
| SCHEMBL2705027 | 0.81 | CYP1A2 (0.56) | CYP1A2CYP2D6PKMSMN1; SMN2NPSR1 | |
| SCHEMBL2705028 | 0.81 | CYP1A2 (0.56) | CYP1A2CYP2D6PKMSMN1; SMN2NPSR1 | |
| Carbamic Acid SCHEMBL7775520 | 0.81 | CYP1A2 (0.53) | CYP1A2CYP2D6PKMSMN1; SMN2NPSR1 | |
| SCHEMBL19553463 | 0.80 | CYP1A2 (0.51) | CYP1A2CYP2D6PKMSMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002367-A1 | BIFUNCTIONAL COMPOUNDS | C4 THERAPEUTICS, INC. | 2023-01-05 | — | — | US | disclosed |
| EP-4054724-A1 | BIFUNCTIONAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2022-09-14 | — | — | EP | disclosed |
| WO-2021086785-A1 | BIFUNCTIONAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002367-A1 | BIFUNCTIONAL COMPOUNDS | ITCH, EGFR, MUC1 | CYP1A2 1204/4885CYP2D6 866/4885PKM 4777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.